Equities
Health CarePharmaceuticals & Biotechnology
  • Price (JPY)4,305.00
  • Today's Change-48.00 / -1.10%
  • Shares traded1.59m
  • 1 Year change55.60%
  • Beta0.8858
Data delayed at least 20 minutes, as of Oct 21 2020 07:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.

  • Revenue in JPY (TTM)734.02bn
  • Net income in JPY190.60bn
  • Incorporated1943
  • Employees7.39k
  • Location
    Chugai Pharmaceutical Co Ltd15F, Nihonbashi Mitsui Tower2-1-1, Nihonbashi-Muro-machiCHUO-KU 103-8324JapanJPN
  • Phone+81 332816611
  • Fax+81 332812828
  • Websitehttps://www.chugai-pharm.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shionogi & Co Ltd324.00bn116.60bn1.63tn5.22k13.762.0612.575.02379.11379.111,050.772,528.890.40021.385.4462,044,240.0014.4014.0115.7715.8382.8480.0135.9830.576.43--0.014925.13-9.404.00-10.9322.63-2.5314.65
Merck KGaA2.11tn177.13bn2.01tn57.52k38.143.084.760.95153.273.2438.9341.360.40591.964.79296,724.903.414.194.535.5561.9965.058.4010.490.6146.270.438710.238.877.2920.632.2310.345.39
Shanghai Fosun Pharmaceutical (Group)449.42bn55.63bn2.13tn31.37k43.084.57--4.741.371.3711.1312.890.36973.025.99906,616.104.986.087.609.1056.4057.0313.4816.560.7985--0.381430.1914.7218.9122.669.4728.766.85
Otsuka Holdings Co Ltd1.42tn146.20bn2.29tn32.99k15.621.2310.061.61263.09263.092,619.583,331.030.54722.583.8243,057,410.005.764.236.995.2068.3266.8110.527.991.91--0.113452.458.07--54.14------
Astellas Pharma Inc1.27tn187.31bn2.77tn15.88k14.882.1110.872.1799.9099.90680.98703.500.6091.743.5480,191,270.008.9610.5612.2014.0579.1376.9514.7115.090.9896--0.253636.12-0.42140.8448-12.087.54-0.82115.92
Alexion Pharmaceuticals, Inc.584.16bn89.27bn2.87tn3.08k33.222.5922.494.913.733.7324.8647.880.35410.86944.441,796,496.005.415.345.815.7591.5890.6615.2818.834.28--0.18860.0020.8117.4411,294.7929.634.55--
Bayer AG5.42tn-909.72bn5.35tn101.17k--1.20--0.9856-7.42-5.7144.2936.340.34511.703.18418,776.00-5.773.25-7.664.1060.2360.77-16.717.560.61915.160.535382.9118.521.0575.47-6.232.254.81
Takeda Pharmaceutical Co Ltd3.24tn119.74bn5.58tn47.50k46.291.188.351.7276.4976.492,073.522,998.370.2481.254.2068,300,180.000.91561.631.082.0768.0668.863.695.280.84441.310.5197164.4456.9313.11-67.28--14.900.00
Chugai Pharmaceutical Co Ltd734.02bn190.60bn7.31tn7.39k37.577.90--9.96115.87115.87446.25551.130.71311.593.6499,272,250.0018.5210.3421.6912.2563.2354.4525.9715.803.69--0.0049.7618.358.2770.3625.3226.1323.87
Data as of Oct 21 2020. Currency figures normalised to Chugai Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

14.20%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 30 Sep 202051.08m3.04%
Capital Research & Management Co. (World Investors)as of 30 Jun 202041.29m2.46%
Nikko Asset Management Co., Ltd.as of 30 Sep 202024.85m1.48%
Daiwa Asset Management Co. Ltd.as of 30 Sep 202024.02m1.43%
Wellington Management Co. LLPas of 09 Oct 202020.93m1.25%
The Vanguard Group, Inc.as of 30 Sep 202019.87m1.18%
Capital Research & Management Co. (Global Investors)as of 30 Sep 202017.18m1.02%
BlackRock Fund Advisorsas of 08 Oct 202014.49m0.86%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 08 Oct 202013.03m0.78%
Norges Bank Investment Managementas of 31 Dec 201911.70m0.70%
More ▼
Data from 31 Dec 2019 - 30 Jun 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.